DelveInsight’s, “Ischemic Stroke Pipeline Insight 2023,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Ischemic Stroke pipeline landscape. It covers the Ischemic Stroke pipeline drug profiles, including Ischemic Stroke clinical trials and nonclinical stage products. It also covers the Ischemic Stroke pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from the Ischemic Stroke Pipeline Report
Discover the recent advances in ischemic stroke medication solutions @ Ischemic Stroke Pipeline Outlook
Recent Developmental Activities in the Ischemic Stroke Treatment Landscape
Ischemic Stroke Overview
Ischemic strokes occur when blood supply is cut off to part of the brain. This type of stroke accounts for the majority of all strokes. The blocked blood flow in an ischemic stroke may be caused by a blood clot or by atherosclerosis, a disease which causes narrowing of the arteries over time. Ischemic strokes can be caused by a blockage anywhere along the arteries feeding the brain. Immediate emergency treatment is critical to surviving a stroke with the least amount of damage to the brain and ability to function. Ischemic strokes occur when blood supply is cut off to part of the brain by a blood clot or narrowing of the arteries. Blood clots may be caused by an irregular heartbeat such as arrhythmia, problems with the heart valve, infection of the heart muscle, hardening of the arteries, blood-clotting disorders, inflammation of the blood vessels, or a heart attack. A less common cause of ischemic stroke occurs when blood pressure becomes too low (hypotension), reducing blood flow to the brain.
Find out more about the latest ischemic stroke drugs and companies @ Ischemic Stroke Treatment Landscape
Ischemic Stroke Emerging Drugs
MultiStem: Athersys, Inc.
The company is developing MultiStem®, a proprietary stem cell product, for the treatment of diseases and conditions in the neurological, inflammatory and immune, and cardiovascular disease areas, as well as other indications. Factors expressed by MultiStem have the potential to deliver a therapeutic benefit in several ways, such as reducing inflammation, protecting damaged or injured tissue, and enhancing the formation of new blood vessels in regions of ischemic injury. These cells exhibit a drug-like profile in that they act primarily through the production of multiple factors that regulate the immune system, protect damaged or injured cells, promote tissue repair and healing, and the cells are subsequently cleared from the body over time. Currently, it is in Phase III stage of clinical trial evaluation to treat Ischemic Stroke.
Elezanumab: Tarveda Therapeutics
Elezanumab (ABT 555) is a fully humanised monoclonal antibody, inhibiting repulsive guidance molecule a (RGMa), being developed by AbbVie, for the treatment of spinal cord injuries and acute ischemic stroke. Currently, it is in Phase II stage of clinical trial evaluation to treat acute ischemic stroke.
LT3001: Lumosa Therapeutics
LT3001, a novel molecule designed to restore occluded blood flow without causing hemorrhage, holds promise as a superior and safer therapy to expand the treatable population and improved the outcome after acute ischemic stroke.
RNS60: Revalesio Corporation
RNS60, is being developed to treat chronic neurodegenerative diseases driven by mitochondrial dysfunction, such as amyotrophic lateral sclerosis (ALS), and to improve recovery from neurological trauma, such as ischemic stroke. RNS60 uniquely activates intracellular signaling pathways that have anti-inflammatory effects and promote mitochondrial biogenesis, cell survival, and differentiation. In addition to protecting neurons and oligodendrocytes in the central nervous system, RNS60 modulates the activity of immune cells to restore cellular homeostasis throughout the body – without the undesirable side effects common to so many of today’s medicines.
Ischemic Stroke Therapeutic Assessment
There are approx. 50+ key companies which are developing the therapies for Ischemic Stroke. The companies which have their Ischemic Stroke drug candidates in the most advanced stage, i.e. phase III include Athersys, Inc.
Learn more about the novel and emerging ischemic stroke pipeline therapies @ Ischemic Stroke Ongoing Clinical Trials
Scope of the Ischemic Stroke Pipeline Report
Table of Content
Dive deep into rich insights for new drugs for ischemic stroke treatment, visit @ Ischemic Stroke Key Companies and Therapies
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/